GlassScriptPhysician profile
Jessica Meredith
NPI 1043074743
$5,313.06
in general payments reported to CMS, 2019-2025
25 companies · $2,920 in 2025
The $2,920 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,393 · 2025: $2,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,059 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,058.82 |
| Education | $254.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,203.47 | 2024-2025 | |
| Janssen Biotech, INC. | $963.67 | 2024-2025 | Tremfya |
| Ucb, INC. | $430.99 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $330.44 | 2024-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $261.41 | 2024-2025 | |
| Lilly USA, LLC | $233.56 | 2024-2025 | Taltz, Ebglyss, Zepbound |
| Galderma Laboratories, L.P. | $225.52 | 2024-2025 | Nemluvio, Dysport, Aklief |
| Biowound Solutions, INC. | $209.07 | 2025 | Bio-Connekt |
| Leo Pharma INC. | $199.19 | 2025 | Adbry, Anzupgo |
| Organon LLC | $198.29 | 2024-2025 | Hadlima, Nexplanon |
| Novartis Pharmaceuticals Corporation | $184.48 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $181.27 | 2024-2025 | Zoryve |
| Incyte Corporation | $139.04 | 2025 | Opzelura, Opzelura |
| Genzyme Corporation | $132.30 | 2024-2025 | |
| Blueprint Medicines Corporation | $118.40 | 2025 | Ayvakit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.89 | 2024-2025 | Jublia, Siliq, Cabtreo |
| Dermavant Sciences, INC. | $33.54 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $25.57 | 2024 | Sotyktu |
| Mimedx Group, INC. | $24.45 | 2024 | |
| Fresenius Kabi USA, LLC | $22.88 | 2024 | Idacio |
| Biocon Biologics INC | $20.03 | 2025 | Hulio |
| Merz North America, INC. | $19.67 | 2024 | |
| Biofrontera INC. | $18.21 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organogenesis INC. | $13.73 | 2025 | Puraply Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Meredith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.